Illumina (NASDAQ:ILMN) Releases Q4 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its fourth quarter earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.91-$0.93 for the period, compared to the consensus estimate of $0.92. The company issued revenue guidance of $1.10 billion, compared to the consensus revenue estimate of $1.07 billion.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Citigroup cut Illumina from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Piper Sandler reduced their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Robert W. Baird increased their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Finally, Stephens increased their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Trading Up 5.5 %

NASDAQ:ILMN opened at $144.22 on Tuesday. Illumina has a one year low of $100.08 and a one year high of $156.66. The company has a market cap of $22.87 billion, a PE ratio of -14.48 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a 50-day moving average of $140.92 and a 200-day moving average of $132.88.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 earnings per share. As a group, equities research analysts expect that Illumina will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.